Skip to main content

Advertisement

Table 1 Baseline demographic and clinical characteristics

From: The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

Characteristic SAXA 2.5 mg q.A.M. (n = 74) SAXA 5 mg q.A.M. (n = 74) SAXA 2.5/5 mg q.A.M. (n = 71) SAXA 5 mg q.P.M. (n = 72) Placebo (n = 74)
Age, years, mean (SD) 55.2 (10.44) 54.7 (9.71) 54.3 (10.93) 55.1 (10.35) 55.6 (10.32)
Age ≥65 years, n (%) 16 (21.6) 12 (16.2) 12 (16.9) 11 (15.3) 13 (17.6)
Gender, n (%)    
 Male 25 (33.8) 38 (51.4) 37 (52.1) 33 (45.8) 35 (47.3)
 Female 49 (66.2) 36 (48.6) 34 (47.9) 39 (54.2) 39 (52.7)
Race, n (%)    
 White 50 (67.6) 49 (66.2) 54 (76.1) 48 (66.7) 53 (71.6)
 Black/African American 5 (6.8) 5 (6.8) 2 (2.8) 8 (11.1) 4 (5.4)
 Asian 18 (24.3) 20 (27) 14 (19.7) 16 (22.2) 17 (23)
 Other 1 (1.4) 0 1 (1.4) 0 0
Weight, kg, mean (SD) 83.8 (16.70) 86.5 (20.71) 85.4 (17.25) 83.3 (19.10) 85.4 (14.40)
BMI, kg/m2, mean (SD) 30.4 (4.84) 31.0 (5.23) 30.6 (4.72) 29.6 (5.37) 31.1 (4.54)
Duration of diabetes, years, mean (SD) 1.2 (1.6) 1.7 (2.4) 2.0 (2.9) 2.0 (5.2) 1.7 (2.8)
HbA1c, %, mean (SD) 8.0 (0.8) 8.0 (0.9) 8.0 (1.1) 7.9 (0.9) 7.8 (1.0)
 <8.0%, n (%) 40 (54.1) 40 (54.1) 37 (52.1) 38 (52.8) 47 (63.5)
 ≥8.0% to < 9.0%, n (%) 23 (31.1) 27 (36.5) 18 (25.4) 24 (33.3) 15 (20.3)
 ≥9.0%, n (%) 11 (14.9) 7 (9.5) 16 (22.5) 10 (13.9) 12 (16.2)
FPG, mg/dL, mean (SD) 158 (33.0) 162 (35.6) 171 (51.8) 160 (44.6) 160 (46.2)
Hypertension, n (%) 40 (54.1) 36 (48.7) 48 (67.6) 41 (56.9) 47 (63.5)
Hypercholesterolemia, n (%) 25 (33.8) 22 (29.7) 32 (45.1) 23 (31.9) 17 (23.0)
Mixed dyslipidemia, n (%) 13 (17.6) 14 (18.9) 15 (21.1) 13 (18.1) 9 (12.2)
CHF, n (%) 6 (8.1) 8 (10.8) 7 (9.9) 4 (5.6) 7 (9.5)
Coronary artery disease, n (%) 9 (12.2) 8 (10.8) 15 (21.1) 8 (11.1) 9 (12.2)
Prior MI, n (%) 4 (5.4) 2 (2.7) 5 (7.0) 4 (5.6) 4 (5.4)
  1. BMI: body mass index; CHF: congestive heart failure; FPG: fasting plasma glucose; HbA1c: glycated hemoglobin; MI: myocardial infarction; SAXA: saxagliptin; SD: standard deviation.